Switch theme
Sign up to access all valuation multiples
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
1990
181
LTM Revenue $217M
LTM EBITDA $11.7M
$787M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nxera Pharma has a last 12-month revenue (LTM) of $217M and a last 12-month EBITDA of $11.7M.
In the most recent fiscal year, Nxera Pharma achieved revenue of $195M and an EBITDA of $0.7M.
Nxera Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nxera Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $217M | XXX | $195M | XXX | XXX | XXX |
| Gross Profit | $164M | XXX | $144M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $11.7M | XXX | $0.7M | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 0% | XXX | XXX | XXX |
| EBIT | -$13.5M | XXX | -$36.7M | XXX | XXX | XXX |
| EBIT Margin | -6% | XXX | -19% | XXX | XXX | XXX |
| Net Profit | -$11.3M | XXX | -$32.8M | XXX | XXX | XXX |
| Net Margin | -5% | XXX | -17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $212M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Nxera Pharma's stock price is JPY 934 (or $6).
Nxera Pharma has current market cap of JPY 84.5B (or $572M), and EV of JPY 116B (or $787M).
See Nxera Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $787M | $572M | XXX | XXX | XXX | XXX | $-0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Nxera Pharma has market cap of $572M and EV of $787M.
Nxera Pharma's trades at 4.0x EV/Revenue multiple, and 1106.8x EV/EBITDA.
Equity research analysts estimate Nxera Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nxera Pharma has a P/E ratio of -50.6x.
See valuation multiples for Nxera Pharma and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $572M | XXX | $572M | XXX | XXX | XXX |
| EV (current) | $787M | XXX | $787M | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 67.5x | XXX | 1106.8x | XXX | XXX | XXX |
| EV/EBIT | -58.2x | XXX | -21.4x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -50.6x | XXX | -17.5x | XXX | XXX | XXX |
| EV/FCF | 40.0x | XXX | -12.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNxera Pharma's last 12 month revenue growth is 23%
Nxera Pharma's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $1.0M for the same period.
Nxera Pharma's rule of 40 is -22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nxera Pharma's rule of X is 63% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nxera Pharma and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Growth | 401% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -22% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 41% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 92% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nxera Pharma acquired XXX companies to date.
Last acquisition by Nxera Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Nxera Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Nxera Pharma founded? | Nxera Pharma was founded in 1990. |
| Where is Nxera Pharma headquartered? | Nxera Pharma is headquartered in Japan. |
| How many employees does Nxera Pharma have? | As of today, Nxera Pharma has 181 employees. |
| Who is the CEO of Nxera Pharma? | Nxera Pharma's CEO is Mr. Christopher Cargill. |
| Is Nxera Pharma publicy listed? | Yes, Nxera Pharma is a public company listed on TKS. |
| What is the stock symbol of Nxera Pharma? | Nxera Pharma trades under 4565 ticker. |
| When did Nxera Pharma go public? | Nxera Pharma went public in 2004. |
| Who are competitors of Nxera Pharma? | Similar companies to Nxera Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Nxera Pharma? | Nxera Pharma's current market cap is $572M |
| What is the current revenue of Nxera Pharma? | Nxera Pharma's last 12 months revenue is $217M. |
| What is the current revenue growth of Nxera Pharma? | Nxera Pharma revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Nxera Pharma? | Current revenue multiple of Nxera Pharma is 3.6x. |
| Is Nxera Pharma profitable? | Yes, Nxera Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nxera Pharma? | Nxera Pharma's last 12 months EBITDA is $11.7M. |
| What is Nxera Pharma's EBITDA margin? | Nxera Pharma's last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of Nxera Pharma? | Current EBITDA multiple of Nxera Pharma is 67.5x. |
| What is the current FCF of Nxera Pharma? | Nxera Pharma's last 12 months FCF is $19.7M. |
| What is Nxera Pharma's FCF margin? | Nxera Pharma's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Nxera Pharma? | Current FCF multiple of Nxera Pharma is 40.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
